Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
A Mixed AdComm: REMS Seems Possible For GSK’s Anemia Drug, Dual Indication Likely Needs More Data
Oct 27 2022
•
By
Sarah Karlin-Smith
GSK’s Daprodustat Went 1 for 2 At Its 26 October US FDA Advisory Committee Meeting • Source: Shutterstock
More from US FDA Performance Tracker
More from Regulatory Trackers